1
CelAgace™ OraRinse Solution for Treatment ofCandidiasis
Epidemiological Study in Subjects With VulvovaginalCandidiases
A Comparative Clinical Trial to Evaluate the Safety and Clinical Equivalence of Clotrimazole Troche/Lozenges USP, 10mg (Unique Pharmaceutical Laboratories, India) With Clotrimazole Troche 10mg (Roxane Laboratories Inc., USA) in Subjects With Oropharyngeal Candidiasis.
Patients With Vulvovaginal Candidiasis
Epidemiological Study About the Evolution of Patients Treated for an Acute Episode of Vulvovaginal Candidiasis
Invasive Candidiasis in Saudi ICUs
Clinical Performance of a Vaginal Pessary (pHyph) in Vulvovaginal Candidiasis
Staging Candidiasis in ICU Patients
Single Dose Versus Two Weeks Course of Fluconazole in the Treatment of Oropharyngeal Candidiasis in HIV Infected Individuals in Tanzania
Fluconazole Versus Micafungin in Neonates WithCandidiasis
Ketoconazole Gel Versus Terconazole Cream for VaginalCandidiasis
Acidophilus for the Treatment and Prevention of OralCandidiasis in Patients Undergoing Radiation Therapy
Comparison of Two Diagnostic Tests in Patients With Suspected Invasive Candidiasis in Internal Medicine Wards and Who Are Currently Timely Treated With Micafungin
NOBICS - NOvel BIomarker In InvasiveCandidiasiS/Candida Sepsis
An Efficacy and Safety Study of Miconazole and Hydrocortisone Cream in the Treatment of VulvarCandidiasis
A Study Of The Safety, Tolerability And Effective Of Voriconazole For The Treatment Of Serious Candida Infection And Candida Infection Of The Throat In Pediatric Patients
The Safety and Efficacy of Intravenous Anidulafungin as a Treatment for Azole-Refractory Mucosal Candidiasis(FRMC)
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
Comparative Efficacy Study of 10 mg Dequalinium Chloride (Fluomizin) in the Treatment of Vulvovaginal Candidiasis
Safety and Equivalence of a Terconazole Vaginal Suppository (Test Product) Compared to the Reference Terconazole Vaginal Suppository in the Treatment of Vulvovaginal Candidiasis
Study of the Efficacy and Tolerance of Intra-vaginal Treatment With a Total Freeze-dried Culture of Lcr Regenerans® in the Prevention of Relapses of Recurrent Vulvovaginal Candidiasis
Pilot Feasibility Study With Patients Who Are at High Risk For Developing Invasive Candidiasis in a Critical Care Setting (MK-0991-067)
Study to Compare the Efficacy and Safety of Micafungin Versus Conventional Amphotericin B for the Treatment of Neonatal Candidiasis
Use of 405nm Blue Light Emitting Diode in the Treatment of Women With Vulvovaginal Candidiasis: a Clinical Trial
CAMB/MAT2203 in Patients With MucocutaneousCandidiasis
Efficacy, Safety LactiSal 1% Gel, LactSal 50 mg, Clotrimazole 100 mg Tablet in Treatment VulvovaginalCandidiasis
Monthly Itraconazole Versus Classic Homeopathy for Treatment of Recurrent Vulvovaginal Candidiasis (RVVC)
Safety and Efficacy of Oral SCY-078 vs. Oral Fluconazole in Subjects With Vulvovaginal Candidiasis
Phase 2B Dose-Ranging Study of PAC113 Mouthrinse in HIV Seropositive Individuals With Oral Candidiasis
Comparative Trial of Micafungin Versus Fluconazole for Treating Esophageal Candidiasis
Trial of Two Dosing Regimens of Micafungin Versus Caspofungin for the Treatment of Esophageal Candidiasis
Fluconazole Prophylaxis for the Prevention of Candidiasisin Infants Less Than 750 Grams Birthweight
MGCD290 and Fluconazole Versus Fluconazole Alone for the Treatment of Moderate to Severe VulvovaginalCandidiasis
A Study of Oral VT-1161 for the Treatment of Acute VaginalCandidiasis (Yeast Infection) in Patients With Recurrent Vaginal Candidiasis
A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
A Study of Oral VT-1161 for the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
The Study Of Fluconazole For Vulvovaginal Candidiasis
Clotrimazole Vaginal Tablet vs Fluconazole for Severe Vulvovaginal Candidiasis
Clotrimazole vs. Mycelex® in Patients With Human Insufficiency Virus (HIV) Infection for the Treatment of Oropharyngeal Candidiasis
Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or InvasiveCandidiasis
The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.
Safety, Tolerability, and Efficacy of Caspofungin Versus Amphotericin B Deoxycholate in the Treatment of InvasiveCandidiasis in Neonates and Infants (MK-0991-064)
Effect of Saccharomyces Cerevisiae on Improving the Effectiveness of Conventional Treatment of Vulvo-vaginalCandidiasis
A Study to Evaluate the Efficacy and Safety of Oral VT-1161 in Patients With Acute Vaginal Candidiasis (Yeast Infection)
β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients
Caspofungin to Prevent Candidiasis in Adults in Hospital Intensive Care Units
A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
A Comparison of Gentian Violet (GV) Mouth Washes, Nystatin, and Ketoconazole Tabs in Treating OropharyngealCandidiasis
A Multicenter Observational Study of Invasive Candida Infections Among ICU Patients in China
The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and InvasiveCandidiasis
Randomized Study of Caspofungin Prophylaxis Followed by Pre-emptive Therapy for Invasive Candidiasis in the Intensive Care Unit (ICU)
Evaluate the Performance of Genetic Amplification by Polymerase Chain Reaction (PCR) and the "Mannan Antigenemia and Antimannan Antibodies Couple as a Means of Diagnosis and a Marker of Follow-up in InvasiveCandidiasis.
Efficacy and Safety of LAS41003 in the Treatment of Intertriginous Candida Infections
A B-D-Glucan Driven Antifungal Stewardship Approach for Invasive Candidiasis
Anidulafungin Candidemia/Invasive Candidiasis Intensive Care Study
Micafungin Versus AmBisome in Invasive Candidiasis and Candidemia
Novel Rinse to Treat in Oral Candidiasis in Cancer Patients
Study of FK463 in the Treatment of Candidemia or InvasiveCandidiasis
Determination of Levels of Micafungin in Neonates Suffering From Systemic Candidiasis and/or Candida Meningitis
A Study to Evaluate the Efficacy and Safety of Micafungin Against Invasive Candidiasis or Candidemia
Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment
Caspofungin for the Treatment of Non-blood Candida Infections (0991-045)
Caspofungin Study for Fungal Infections in Adults in Critical Care Settings
Open-Label Study to Evaluate the Efficacy and Safety of SCY-078 in Patients With Candidiasis Caused by Candida Auris (CARES)
Risk Of Severe Hepatic Injury In Patients With InvasiveCandidiasis Treated With Echinocandins
Effect of Saccharomyces Cerevisiae on Vulvo-vaginalCandidiasis
CRITIC - Treatment of Candidemia and InvasiveCandidiasis
Terconazole Vaginal Suppository vs Fluconazole for the Treatment of Severe Vulvovaginal Candidiasis
Micafungin Versus Fluconazole in the Treatment of InvasiveCandidiasis and Candidemia
This Is An Open-Label, Non-Comparative Study Designed To Evaluate A Short Course Of IV Anidulafungin, Followed Optionally By Oral Voriconazole, For The Treatment Of Candidemia And Invasive Candidiasis
A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations
Prevention of Recurrent Vulvovaginal Candidiasis With Lactibiane Candisis 5M®
Incidence of Oral Candidiasis, Prevalence of C. Dubliniensis in HIV Patients and In-vitro Azole Susceptibility
Study of Micafungin in Patients With Invasive Candidiasisor Candidemia
Clinical Significance of Smear or Culture Positive for Candida Spp. From Sputum Three Times a Week
Diabetes Mellitus and Vulvovaginal Candidiasis
A Randomized, Prospective, Double-Blind Study Comparing Fluconazole With Placebo for Primary and Secondary Prophylaxis of Mucosal Candidiasis in HIV-Infected Women
ProF-001_Phase IIa
An Open Study of the Effect of Itraconazole Oral Solution for the Treatment of Fluconazole Refractory OropharyngealCandidiasis in HIV-Positive Subjects.
Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.
Nystatin Pastilles for the Prevention of Oral Candidiasis in Patients With AIDS or ARC
Impact of a Loading Dose of Caspofungin in InvasiveCandidiasis in ICU Patients
A Comparison of SCH 56592 and Fluconazole in the Treatment of Oropharyngeal Candidiasis (OPC) in HIV-Positive Patients
Evaluate Efficacy, Tolerability & Safety of Combination of Clindamycin and Ketoconazole for the Treatment of Mixed-Type Vaginosis, Bacterial Vaginosis and Candidiasis
PEACE: Pediatric Antifungal Comparative Effectiveness
A Multicenter, Randomized, Double-Blind, Comparative Study to Evaluate the Safety, Tolerability, and Efficacy of 2 Dosing Regimens of an Antifungal Drug in the Treatment of Fungal Infections in Adults (0991-801)(COMPLETED)
A Study to Compare the Efficacy and Safety of a Combination of Ketoconazole and Clindamycin Compared to Tetracycline/Amphotericin B Combination Cream for the Treatment of Bacterial Vaginosis and Vaginal Candidiasis(P08077)
Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection
Funguria in Hospitalized Patients
A Study to Compare the Use of Fluconazole as Continuous Therapy Versus Periodic Therapy in HIV-Positive Patients With Recurrent Thrush
Safety and Effectiveness of Fluconazole Versus SCH 56592 to Treat Thrush in HIV-Positive Patients
Safety and Effectiveness of Giving L-743,872 to Patients With Thrush That Has Not Been Cured With Fluconazole
Safety and Effectiveness of Giving Lamisil to HIV-Positive Subjects With Thrush Who Have Not Responded to Fluconazole Treatment
Comparative Randomized Study of the Efficacy, Safety, and Toleration of Fluconazole Oral Suspension or Nystatin Oral Suspension in the Treatment of Patients With Oropharyngeal Candidiasis in Association With the Acquired Immunodeficiency Syndrome
Oral SCY-078 vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
Immunological Interaction Between the Host and Candida Albicans Biofilm
Early Discontinuation of Empirical Antifungal Therapy and Biomarkers
Pharmacokinetics (PK) Study of a Fluconazole Loading Dose in Infants and Toddlers
Anidulafungin Versus Fluconazole in the Treatment of Candidemia
Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation
- Candidiasis, Oral
- Drug: silver citrate complex and acemannan
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Texas A&M University College of Dentistry
Dallas, Texas, United States
- Vulvovaginal Candidiases
- Observational Model: Cohort
- Time Perspective: Prospective
- Instituto Palacios
Madrid, Spain
- Oropharyngeal Candidiasis
- Drug: Unique Pharmaceutical Laboratories, India
- Drug: Roxane Laboratories Inc., USA
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
- Grant Government Medical College & Sir JJ group of Hospital
Mumbai, Maharashtra, India - Curie Manavata Cancer Centre
Nashik, Maharashtra, India - Manas Hospital
Nashik, Maharashtra, India - (and 23 more...)
- Vulvovaginal Candidiasis
- Drug: EPP-AF Gel 1%
- Drug: EPP-AF Gel 2%
- Drug: Clotrimazole
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Clinical Hospital of Sao Paulo University
Ribeirao Preto, Sao Paulo, Brazil
- Candidiasis, Vulvovaginal
- Other: Clotrimazole
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Health Services Research
- Instituto Palacios
Madrid, Spain
- Invasive Candidiasis
- Observational Model: Cohort
- Time Perspective: Prospective
- King Abdulaziz Medical City
Riyadh, Saudi Arabia - King Fahad Medical City
Riyadh, Saudi Arabia
- Vulvovaginal Candidiasis
- Device: pHyph, Gedea pessary
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Hoftekliniken
Helsingborg, Sweden - Annerokliniken
Hofterup, Sweden
- Candidiasis
- Biological: Tests for candidiasis
- Observational Model: Cohort
- Time Perspective: Prospective
- CHU de Nîmes
Nimes, Gard, France - CHU de Montpellier
Montpellier Cedex 05, France
- Oropharyngeal Candidiasis
- Drug: fluconazole
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
- ART clinic Muhimbili National Hospital/Muhimbili University College of Health Sciences
Dar es Salaam, Tanzania
- Candidiasis
- Drug: Fluconazole
- Drug: Micafungin
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Antwerp, Rocourt, Liège, Louvain, Namur, Belgium
- Paris, Lyon, Saint-Pierre de la Réunion, France
- Roma, Torino, Catania, Foggia, Reggio Emilia, Italy
- (and 2 more...)
- Vaginal Candidiasis
- Drug: Ketoconazole
- Drug: Terconazole
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Oral Candidiasis
- Dietary Supplement: Acidophilus
- Dietary Supplement: Acidolphilus
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Summa Health System
Akron, Ohio, United States
- Invasive Candidiasis
- Diagnostic Test: 1,3-β-D-glucan quantification
- Drug: Micafungin
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
- Osp. Generale Regionale F. Miulli
Acquaviva Delle Fonti, Italy - Nuovo Ospedale Civile S. Agostino-Estense
Baggiovara, Italy - Ospedale di Bussolengo
Bussolengo, Italy - (and 17 more...)
- Invasive Candidiasis
- Observational Model: Cohort
- Time Perspective: Prospective
- Medical University of Graz
Graz, Stmk, Austria
- Vulva; Candidiasis
- Drug: Miconazole plus Hydrocortisone
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Candidiasis
- Drug: voriconazole
- Allocation: Non-Randomized
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Tongji Hospital of Tongji Medical College of Huazhong University of Science and Technology
Wuhan, Hubei, China - Beijing Children's Hospital, Capital University of Medical Sciences
Beijing, China - Fakultni nemocnice Brno - Klinika detske onkologie
Brno, Czech Republic - (and 11 more...)
- Candidiasis
- Drug: Anidulafungin, VER002
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Versicor, Inc.
King of Prussia, Pennsylvania, United States
- Vulvovaginal Candidiasis
- Biological: NDV-3A
- Biological: NDV-3
- Biological: Placebo
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
- Precision Trials LLC
Phoenix, Arizona, United States - Arkansas Women's Center
Little Rock, Arkansas, United States - Women's Health Care Research Corp
San Diego, California, United States - (and 17 more...)
- Vulvovaginal Candidiasis
- Drug: Fluomizin vaginal tablets
- Drug: Canesten vaginal tablets
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
- Siriraj Gynaecologic ID and Female STD Unit, Department of Obstetrics & Gynaecology, Faculty of Medicine Siriraj Hospital, Mahidol University
Bangkok, Bangkok Noi district, Thailand
- Vulvovaginal Candidiasis
- Drug: Terconazole Vaginal Suppository
- Drug: Terazol Vaginal Suppository
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
- Candidiasis, Vulvovaginal
- Drug: Lcr Regenerans
- Drug: Placebo
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
- Probionov
Aurillac, France
- Invasive Candidiasis
- Drug: Caspofungin acetate
- Drug: Placebo
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
- Candidiasis
- Drug: micafungin
- Drug: amphotericin B deoxycholate
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
- Children's Hospital of Orange County
Orange, California, United States - UMDNJ/Robert Wood Johnson Medical School
New Brunswick, New Jersey, United States - Duke University
Durham, North Carolina, United States - (and 14 more...)
- Candidiasis, Vulvovaginal
- Device: Blue LED 405 nm
- Other: Questionnaire of anamnesis
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Candidiasis, Chronic Mucocutaneous
- Drug: Amphotericin B
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- National Institute of Allergy and Infectious Disease (NIAID)
Bethesda, Maryland, United States
- Vulvovaginal Candidiasis
- Device: LactiSal vaginal gel 1%
- Device: LactiSal vaginal tablet 50mg
- Drug: Clotrimazole vaginal tablet 100mg
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Vulvovaginal Candidiasis
- Drug: itraconazole
- Drug: lactobacillus gasseri
- Drug: classic homeopathy (carcinosin M, nux vomica, pulsatilla M, ferrum metallicum, sepia M, etc. as prescribed)
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Vienna Medical School
Vienna, Austria
- Vulvovaginal Candidiasis
- Drug: SCY-078
- Drug: Fluconazole
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Investigator)
- Primary Purpose: Treatment
- Hospital Dr. Francisco E. Moscoso Puello
Santo Domingo, Dominican Republic - Instituto Dermatologico y Cirugia de Piel
Santo Domingo, Dominican Republic
- Oral Candidiasis
- Drug: PAC113
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Outcomes Assessor)
- Primary Purpose: Treatment
- Rosedale Infectious Disease
Huntersville, North Carolina, United States
- Candidiasis, Oral
- Drug: Micafungin
- Drug: Fluconazole
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
- Abadia Uberaba, Brazil
- Barretos, Brazil
- 5 Sites
Belo Horizonte, Brazil - (and 34 more...)
- Candidiasis, Oral
- Drug: micafungin
- Drug: caspofungin
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
- 5 Sites
Buenos Aires, Argentina - Cordoba, Argentina
- Neuquen, Argentina
- (and 28 more...)
- Candidiasis
- Drug: fluconazole
- Drug: placebo
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
- University of Alabama at Birmingham
Birmingham, Alabama, United States - University of Arkansas for Medical Sciences
Little Rock, Arkansas, United States - Arkansas Childrens Hospital
Little Rock, Arkansas, United States - (and 30 more...)
- Vulvovaginal Candidiasis
- Drug: MGCD290
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
- University of Alabama at Birmingham
Birmingham, Alabama, United States - Women's Health Care Research Corp.
San Diego, California, United States - Altus Research
Lake Worth, Florida, United States - (and 16 more...)
- Recurrent Vulvovaginal Candidiasis
- Drug: VT-1161 150 mg capsule
- Drug: Fluconazole 150 mg
- Other: Placebo
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
- 43
Phoenix, Arizona, United States - 34
Tucson, Arizona, United States - 39
Encino, California, United States - (and 41 more...)
- Recurrent Vulvovaginal Candidiasis
- Drug: VT-1161
- Drug: Placebo
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
- 31123
Birmingham, Alabama, United States - 31108
San Diego, California, United States - 31139
Lauderdale Lakes, Florida, United States - (and 22 more...)
- Recurrent Vulvovaginal Candidiasis
- Drug: VT-1161
- Drug: Placebo
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
- 31215
Phoenix, Arizona, United States - 31227
Little Rock, Arkansas, United States - 31217
Los Angeles, California, United States - (and 11 more...)
- Vulvovaginal Candidiasis
- Drug: Fluconazole
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Ai WOMEN'S CLINIC
Asahikawa, Hokkaido, Japan - Shirokane Ladies' Clinic
Minato-ku, Tokyo, Japan - Takane Medical Clinic
Shinagawa-ku, Tokyo, Japan - (and 7 more...)
- Candidiasis, Vulvovaginal
- Drug: Clotrimazole vaginal tablet
- Drug: Fluconazole
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Peking University Shenzhen Hospital
Shenzhen, Guangdong, China
- Candidiasis, Oral
- Drug: Roxanes's clotrimazole troches
- Drug: Mycelex® troches
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single
- Primary Purpose: Treatment
- Candidiasis
- Drug: Eraxis (anidulafungin)
- Drug: Diflucan (fluconazole)
- Drug: Vfend (voriconazole)
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Pfizer Investigational Site
Birmingham, Alabama, United States - Pfizer Investigational Site
Birmingham, Alabama, United States - Pfizer Investigational Site
Little Rock, Arkansas, United States - (and 40 more...)
- Candidiasis
- Drug: Anidulafungin, VER002
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Versicor, Inc.
King of Prussia, Pennsylvania, United States
- Candidiasis, Invasive
- Drug: Caspofungin
- Drug: Amphotericin B Deoxycholate
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
- Vulvo-vaginal Candidiasis
- Dietary Supplement: Saccharomyces cerevisiae
- Dietary Supplement: Placebo
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Supportive Care
- Eurofins Optimed
Gières, France
- Candidiasis, Vulvovaginal
- Drug: VT-1161
- Drug: Fluconazole
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
- Altus Research
Lake Worth, Florida, United States - Healthcare Clinical Data, Inc
North Miami, Florida, United States - SUNY Downstate Medical Center
Brooklyn, New York, United States - (and 5 more...)
- Invasive Candidiasis
- Drug: Preemptive Therapy with Anidulafungin
- Drug: Empiric antifungal therapy based on physician discretion.
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Duke University Medical Center
Durham, North Carolina, United States
- Candidiasis
- Drug: Caspofungin
- Primary Purpose: Treatment
- National Cancer Institute (NCI)
Bethesda, Maryland, United States
- Recurrent Vulvovaginal Candidiasis
- Drug: VT-1161
- Drug: Placebo
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
- University of Alabama Birmingham
Birmingham, Alabama, United States - Precision Trials
Phoenix, Arizona, United States - NEA Baptist Clinic
Jonesboro, Arkansas, United States - (and 29 more...)
- Candidiasis, Oral
- Drug: Gentian violet 1% solution
- Drug: Gentian violet 0.00165% solution
- Drug: Nystatin solution
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Treatment
- Queen Elizabeth Central Hospital, Paediatric Dept, Box 360
Blantyre, Malawi
- Candidiasis
- Observational Model: Case-Only
- Time Perspective: Prospective
- Gulou District
Nanjing, Jiangsu, China
- Candidiasis
- Drug: Anidulafungin
- Drug: Fluconazole
- Allocation: Randomized
- Intervention Model: Single Group Assignment
- Masking: Double
- Primary Purpose: Treatment
- Versicor, Inc.
King of Prussia, Pennsylvania, United States
- Invasive Candidiasis
- Drug: Caspofungin
- Drug: Normal Saline
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
- University of Alabama at Birmingham
Birmingham, Alabama, United States - University of Southern California
Los Angeles, California, United States - University of Colorado
Denver, Colorado, United States - (and 9 more...)
- Invasive Candidiasis; Treatment With Echinocandin
- Biological: Blood sample taken on the day the treatment is initiated
- Biological: Blood sample taken on day 3 after initiation of treatment
- Biological: Blood sample taken on day 5 after initiation of
- (and 2 more...)
- Observational Model: Case-Only
- Time Perspective: Prospective
- CHU de DIJON
Dijon, France
- Candidiasis
- Drug: LAS41003
- Drug: LAS189962
- Drug: LAS189961
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
- Investigational Site #5
Augsburg, Germany - Investigational Site #4
Bad Saarow, Germany - Investigational Site #2
Berlin, Germany - (and 3 more...)
- Invasive Candidiases
- Abdominal Infection
- Diagnostic Test: De-escalation
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Single (Care Provider)
- Primary Purpose: Other
- Azienda Ospealiero Universitaria di Bologna Policlinico S.Orsola-Malpighi
Bologna, Italy
- Invasive Candidiasis
- Drug: Anidulafungin
- Drug: Fluconazole
- Drug: Voriconazole
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Pfizer Investigational Site
Wien, Austria - Pfizer Investigational Site
Brussels, Belgium - Pfizer Investigational Site
Brussel, Belgium - (and 58 more...)
- Candidiasis
- Drug: Micafungin
- Drug: Liposomal Amphotericin B
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
- Birmingham, Alabama, United States
- Orange, California, United States
- Denver, Colorado, United States
- (and 34 more...)
- Candidiasis, Oral
- Thrush
- Candidiasis
- Drug: Frio Oral Rinse
- Observational Model: Case-Only
- Time Perspective: Prospective
- University of Missouri at Kansas City, School of Dentistry
Kansas City, Missouri, United States - Cancer Therapy and Researh Center
San Antonio, Texas, United States
- Candidiasis
- Drug: FK463
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Medizinische Univ.-Klinik
Graz, Austria - Krankenhaus Elisabethinen Linz
Linz, Austria - Hopital Henri Mondor, Dervice d'Hematologie Clinique
Creteil, France - (and 20 more...)
- Candidiasis, Systemic
- Candida Meningitis
- Drug: Micafungin
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Site IT39001
Rome, Italy - Site IT39002
Rome, Italy
- Candidemia
- Candidiasis
- Drug: Micafungin
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Beijing, China
- Changsha, China
- Chengdu, China
- (and 12 more...)
- Vulvovaginal Candidiasis
- Drug: arasertaconazole nitrate
- Drug: placebo
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Treatment
- Ferrer Internacional S.A.
Barcelona, Spain
- Candidiasis
- Drug: MK0991, caspofungin acetate/Duration of Treatment: variable
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Candidiasis
- Drug: Caspofungin
- Other: Placebo
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double
- Primary Purpose: Prevention
- University of Alabama Hospital - Infectious Diseases
Birmingham, Alabama, United States - University of Southern California - Infectious Diseases
Los Angeles, California, United States - Harbor UCLA Medical Center - Medicine - Infectious Diseases
Torrance, California, United States - (and 23 more...)
- Candidiasis, Invasive
- Candidemia
- Drug: SCY-078
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Scynexis, Inc.
Jersey City, New Jersey, United States - St John's Medical College and Hospital
Bangalore, Karnataka, India - Amrita Institute of Medical Sciences (AIMS)
Kanayannur, Kochi, India - (and 2 more...)
- Invasive Candidiasis
- Candidemia
- Other: Does not apply
- Observational Model: Case Control
- Time Perspective: Retrospective
- Candidiasis, Vulvovaginal
- Device: Saccharomyces cerevisiae
- Device: Placebo
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Supportive Care
- Dermscan
Villeurbanne, France
- Candidemia
- Invasive Candidiasis
- Drug: AmBisome
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Gilead Sciences Srl
Milan, Italy
- Vulvovaginal Candidiasis
- Drug: Terconazole Vaginal Suppository
- Drug: Fluconazole
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Peking University Shenzhen Hosptal
Shenzhen, Guangdong, China
- Invasive Candidiasis
- Candidemia
- Drug: Micafungin
- Drug: fluconazole
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Taipei, Republic of China, Taiwan
- Candidemia
- Invasive Candidiasis
- Drug: Anidulafungin
- Drug: Voriconazole
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Pfizer Investigational Site
Brasilia, DF, Brazil - Pfizer Investigational Site
Curitiba, PR, Brazil - Pfizer Investigational Site
Rio de Janeiro, RJ, Brazil - (and 10 more...)
- Vulvovaginal Candidiasis
- Drug: Butoconazole Nitrate Vaginal Cream
- Drug: Placebo
- Drug: Gynazole 1 vaginal cream
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Care Provider)
- Primary Purpose: Treatment
- PharmaNet, Inc. (PharmaNet)
Charlotte, North Carolina, United States
- Vaginal Candidiasis
- Dietary Supplement: Lactibiane candisis 5M
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Prevention
- Pileje
37 Quai de Grenelle, Paris, France
- Candidiasis
- HIV Infections
- Time Perspective: Prospective
- Duval County Department of Health. Boulevard Comprehensive Care Center
Jacksonville, Florida, United States
- Candidiasis
- Candidemia
- Drug: Micafungin
- Drug: Caspofungin
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
- Birmingham, Alabama, United States
- Little Rock, Arkansas, United States
- Los Angeles, California, United States
- (and 164 more...)
- Pulmonary Candidiasis
- Drug: fluconazole
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Diagnostic
- Beijing Chaoyang Hospital,Affiliate of Capital Medical University
Beijing, Beijing, China
- Diabetes Mellitus
- Vulvovaginal Candidiasis
- Drug: Boric
- Drug: Fluconazole
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Dr Ravinder Goswami
Delhi, India
- Candidiasis
- Candidiasis, Esophageal
- HIV Infections
- Drug: Fluconazole
- Masking: Double
- Primary Purpose: Treatment
- Community Consortium of San Francisco
San Francisco, California, United States - Denver CPCRA / Denver Public Hlth
Denver, Colorado, United States - Wilmington Hosp / Med Ctr of Delaware
Wilmington, Delaware, United States - (and 13 more...)
- Vulvovaginal Candidiasis(VVC)
- Drug: Candiplus
- Drug: Clotrimazole
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Triple (Participant, Care Provider, Investigator)
- Primary Purpose: Treatment
- Medical University Innsbruck
Innsbruck, Austria - Bezirkskrankenhaus Schwaz
Schwaz, Austria - Medical University Vienna
Vienna, Austria
- Candidiasis, Oral
- HIV Infections
- Drug: Itraconazole
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Univ of Alabama at Birmingham
Birmingham, Alabama, United States - Univ of Arkansas for Med Sciences
Little Rock, Arkansas, United States - East Bay AIDS Ctr
Berkeley, California, United States - (and 15 more...)
- Candidiasis, Esophageal
- HIV Infections
- Drug: Itraconazole
- Drug: Fluconazole
- Masking: Double
- Primary Purpose: Treatment
- Dr Eskild A Petersen
Tucson, Arizona, United States - Los Angeles County - USC Med Ctr
Los Angeles, California, United States - UCSD Med Ctr
San Diego, California, United States - (and 15 more...)
- Candidiasis, Oral
- HIV Infections
- Drug: Nystatin
- Primary Purpose: Treatment
- Birmingham Veterans Administration Med Ctr / Univ of Alabama
Birmingham, Alabama, United States - Bristol - Myers Squibb Co
Princeton, New Jersey, United States
- Candida Infections
- Observational Model: Cohort
- Time Perspective: Prospective
- Reanimation Medicale et Infectieuse-Hopital Bichat
Paris, France
- Candidiasis, Oral
- HIV Infections
- Drug: Posaconazole
- Drug: Fluconazole
- Masking: Double
- Primary Purpose: Treatment
- Tucson Veterans Administration Med Ctr
Tucson, Arizona, United States - Northeast Arkansas Clinic
Jonesboro, Arkansas, United States - Miami Veterans Administration Med Ctr
Miami, Florida, United States - (and 50 more...)
- Candidiasis
- Bacterial Vaginosis
- Drug: Clindamycin 100mg and Ketoconazole 400mg
- Drug: Tetracycline 100mg and Amphotericin B 50mg
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Vox Femina
Jundiaí, SP, Brazil
- Pediatric Invasive Candidiasis
- Drug: Observational antifungal therapy
- Observational Model: Cohort
- Time Perspective: Prospective
- Arkansas Children's Hospital
Little Rock, Arkansas, United States - Children's Hospital of Orange County
Orange, California, United States - Lucile Packard Children's Hospital at Stanford
Palo Alto, California, United States - (and 32 more...)
- Invasive Candidiasis
- Drug: caspofungin acetate
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Double (Participant, Investigator)
- Primary Purpose: Treatment
- Vaginosis, Bacterial
- Candidiasis, Vulvovaginal
- Drug: 100 mg clindamycin /800 mg ketoconazole vaginal ovule
- Drug: 100 mg tetracycline hydrochloride /50 mg amphotericin B cream
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Recurrent Vulvovaginal Candidiasis
- Biological: PEV7C1
- Biological: PEV7C9
- Biological: PEV7B2
- Biological: PEV7B1
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
- Primary Purpose: Prevention
- Covance Clinical Research Unit AG
Allschwil, Basel, Switzerland - CHUV, Vaccine and Immunotherapy Center
Lausanne, Switzerland
- Candidiasis
- Time Perspective: Prospective
- Cedars Sinai Medical Center
Los Angeles, California, United States - UCLA Center For Vaccine Research
Torrance, California, United States
- Candidiasis, Oral
- HIV Infections
- Drug: Fluconazole
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Univ of Southern California / LA County USC Med Ctr
Los Angeles, California, United States - UCLA CARE Ctr
Los Angeles, California, United States - Univ of California / San Diego Treatment Ctr
San Diego, California, United States - (and 51 more...)
- Candidiasis, Oral
- HIV Infections
- Drug: Posaconazole
- Drug: Fluconazole
- Masking: Double
- Primary Purpose: Treatment
- East Bay AIDS Ctr
Berkeley, California, United States - ViRx Inc
San Francisco, California, United States - Kaiser Foundation Hospital
San Francisco, California, United States - (and 15 more...)
- Candidiasis, Oral
- HIV Infections
- Drug: L-743,872
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Carol Sable
Rahway, New Jersey, United States
- Candidiasis, Oral
- HIV Infections
- Drug: Terbinafine hydrochloride
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- Therafirst Med Ctr
Fort Lauderdale, Florida, United States - Associates in Research
Fort Myers, Florida, United States - Clireco Inc
Tamarac, Florida, United States - (and 6 more...)
- Candidiasis, Oral
- HIV Infections
- Drug: Nystatin
- Drug: Fluconazole
- Intervention Model: Parallel Assignment
- Primary Purpose: Treatment
- California Med Research Group
Fresno, California, United States - UCSF Hosp
San Francisco, California, United States - Johns Hopkins School of Medicine
Baltimore, Maryland, United States - (and 2 more...)
- Mycoses
- Candidiasis, Invasive
- Candidemia
- Drug: SCY-078
- Drug: Fluconazole
- Drug: Micafungin
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- University of Alabama at Birmingham
Birmingham, Alabama, United States - UC Davis Medical Center
Sacramento, California, United States - University of Colorado Denver
Aurora, Colorado, United States - (and 27 more...)
- Candidiasis
- Observational Model: Case Control
- Time Perspective: Retrospective
- Universitair Ziekenhuis Leuven
Leuven, Flemish Brabant, Belgium
- Invasive Candidiasis
- Other: Biomarker strategy
- Other: Routine strategy
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Hôpital Roger Salengro, CHU
Lille, France
- Candidiasis
- Drug: Fluconazole Loading Dose
- Drug: Fluconazole Loading Dose & High Dose
- Allocation: Non-Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Treatment
- Duke Univeristy Medical Center
Durham, North Carolina, United States
- Candida
- Candidiasis
- Drug: Anidulafungin
- Primary Purpose: Treatment
- National Cancer Institute (NCI)
Bethesda, Maryland, United States
- Candidiasis, Vulvovaginal
- Device: Lcr Regenerans® vaginal capsules
- Device: Lcr Regenerans® vaginal tablet
- Allocation: Randomized
- Intervention Model: Parallel Assignment
- Masking: None (Open Label)
- Primary Purpose: Other
- BIOSE
Aurillac, France
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου